Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue.

@article{Uckaya2005ImprovementOM,
  title={Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue.},
  author={Gokhan Uckaya and Philippe Delagrange and Alain Chavanieu and G{\'e}rard Grassy and M F Berthault and Alain Ktorza and Erol Cerasi and Gil Leibowitz and Nurit Kaiser},
  journal={The Journal of endocrinology},
  year={2005},
  volume={184 3},
  pages={
          505-13
        }
}
Glucagon-like peptide 1 (GLP-1) analogues are considered potential drugs for type 2 diabetes. We studied the effect of a novel GLP-1 analogue, S 23521 ([a8-des R36] GLP-1-[7-37]-NH2), on the metabolic state and beta-cell function, proliferation and survival in the Psammomys obesus model of diet-induced type 2 diabetes. Animals with marked hyperglycaemia after 6 days of high-energy diet were given twice-daily s.c. injection of 100 microg/kg S 23521 for 15 days. Food intake was significantly… Expand
Obesity, Insulin Resistance, and Metabolic Syndrome: A Study in WNIN/Ob Rats from a Pancreatic Perspective
TLDR
Results advocate that inflammation was the major precipitating factor to cause islet cell dysfunctions (in situ and in vitro) in these Mutant rats compared to their Lean littermates and parental Control. Expand
Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus
TLDR
It is suggested that liraglutide restores normoglycaemia and improves glycaemic control in P. obesus by increasing their insulin content and improving the function of the beta-cells, in contrast to vildagliptin, which does not improve glycaemia control and neither reduced blood glucose nor altered HED-induced increases in BCM or pancreatic insulin content. Expand
A Review of Islet of Langerhans Degeneration in Rodent Models of Type 2 Diabetes
TLDR
The importance, advantages, and limitations of rodent models of TTDM in relation to the histopathological changes that characterize islet degeneration are reviewed and placed into the context of changes in islet histological appearances. Expand
Animal models in type 2 diabetes research: an overview.
TLDR
This review gives an overview on the animal models of type 2 diabetes with reference to their origin/source, characteristic features, underlying causes/mechanism, advantages and disadvantages to the investigators in diabetes research. Expand
Diet-induced diabetes in the sand rat (Psammomys obesus).
TLDR
The present review describes the P. obesus of the Hebrew University colony, with emphasis on its use for the study of β-cell dysfunction in type 2 diabetes. Expand
Gastrointestinal hormones and the regulation of β‐cell mass
TLDR
Type 2 diabetes occurs due to a relative deficit in β‐cell mass or function and the protein kinase A pathway is central to this process because it directly regulates proliferative and anti‐apoptotic genes and transactivates several signaling cascades, including Akt and mitogen‐activated protein kinases. Expand
Péptidos anorexigénicos y su participación en la conducta alimentaria
TLDR
In this review the role of important anorexigenic neuropeptides on food intake and body weight regulation is summarized. Expand
Chapter 54 – Sand Rat
TLDR
This chapter provides limited information on basic species biology and husbandry, and instead concentrates on the research uses of sand rats, a rodent belonging to the subfamily Gerbillinae. Expand
Revisiting amino acids and peptides as anti-glycation agents.
TLDR
The chemical reactions involved in glycation and the formation of advanced glycation end-products (AGEs) and possible/probable intervention sites and mechanism of action of the reported amino acids/peptides are discussed. Expand
Investigation of the Effect of Quercetin on Neurological Alterations During Type 2 Diabetes Mellitus in Swiss Albino Mice
TLDR
Using nanofiltration membranes for the recovery of phosphorous with a second type of technology for the Recovery of nitrogen is suggest to be a viable process and the process of recovery is described in more detail. Expand
...
1
2
...

References

SHOWING 1-10 OF 55 REFERENCES
The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.
TLDR
The long-acting GLP-1 derivative, NN2211, restored beta-cell responsiveness to physiological hyperglycemia in type 2 diabetic subjects. Expand
Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.
TLDR
A marked effect of GLP-1 on appetite is demonstrated by showing enhanced satiety and reduced energy intake in patients with diabetes type 2. Expand
Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice
TLDR
The results suggest that Ex4 treatment delays the onset of diabetes in 6–8 week old db/db mice, through a mechanism involving Akt1 and expansion of the functional beta-cell mass. Expand
Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats.
Glucose homeostasis in mammals is maintained by insulin secretion from the beta-cells of the islets of Langerhans. Type 2 diabetes results either from primary beta-cell failure alone and/or a failureExpand
Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
TLDR
Due to the dose-dependent inhibition of gastric emptying, lower GLP-1 doses than previously used may be as suitable for glucose control in patients with type 2 diabetes. Expand
Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
TLDR
Findings in the GK model indicated, for the first time, that GLP-1 or Ex-4 treatment limited to the prediabetic period delays the installation and limits the severity of type 2 diabetes. Expand
Interaction between genetic and dietary factors determines beta-cell function in Psammomys obesus, an animal model of type 2 diabetes.
TLDR
It is concluded that the insulin-resistant P. obesus has an inherent deficiency in insulin release, and genetic predisposition and beta-cell maladaptation to nutritional load seem to determine together the progression to overt diabetes in this species. Expand
Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene
TLDR
It is demonstrated that GLP1 plays a central role in the regulation of glycemia; however, disruption of GLP 1/GLP1R signaling in the central nervous system is not associated with perturbation of feeding behavior or obesity in vivo. Expand
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.
TLDR
Ex vivo immunostaining showed that the metabolic changes observed in rats treated with GLP-1 were associated with an increase in cell proliferation of the endocrine and exocrine component of the pancreas. Expand
Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.
TLDR
The present series of experiments show that GLP-1 is fully capable of inhibiting food intake in rats via a peripherally accessible site and may prove efficient as weight-reducing therapeutic agents for overweight patients with type 2 diabetes. Expand
...
1
2
3
4
5
...